The victory gives Pfizer a long-awaited foothold in the booming weight-loss drug market as Novo retreats amid U.S. antitrust fears.
NEW YORK (November 7, Market Insider) — Pfizer has emerged victorious in one of the most dramatic biotech bidding wars of 2025, clinching a $10 billion acquisition of Metsera, a U.S.-based obesity drug developer, after rival Novo Nordisk abruptly exited the race citing antitrust risks.
The deal, announced late Friday, marks Pfizer’s biggest push yet into the obesity drug arena — a field expected to exceed $150 billion globally by the early 2030s. For Novo, whose blockbuster Wegovy once dominated the market before being outflanked by Eli Lilly, the defeat is a major strategic setback.
Pfizer Secures a Costly but Strategic Victory
Under the agreement, Pfizer will pay $86.25 per share in cash, including $65.60 upfront and an additional $20.65 per share in contingent payments, Metsera said. The price represents a 3.7% premium to Friday’s close and a stunning escalation from Pfizer’s $7.3 billion offer in September.
Novo Nordisk confirmed on Saturday that it would not raise its bid further, calling its final proposal the “maximum value” for Metsera.
“Following a competitive process and after careful consideration, Novo Nordisk will not increase its offer,” the Danish company said, adding that it will refocus on its internal obesity pipeline and future M&A opportunities.
Metsera’s board endorsed Pfizer’s offer, calling it the best path forward for shareholders and noting that U.S. regulators had raised antitrust concerns about a merger with Novo. The Federal Trade Commission reportedly warned both firms that such a deal risked violating competition laws.
A “Game of Thrones” Bidding War
The takeover saga played out over weeks of escalating offers and regulatory twists, drawing comparisons to Pfizer’s historic $90 billion acquisition of Warner-Lambert in 2000 to gain control of Lipitor.
“While this is a smaller deal, Pfizer clearly sees Metsera’s obesity pipeline as vital to its future,” said former Pfizer R&D chief John LaMattina.
The fierce back-and-forth sent Metsera’s shares soaring nearly 60% in a week, boosting its market cap to $8.75 billion. “This was a Game of Thrones-level contest,” quipped Peter Kolchinsky, managing partner of RA Capital, one of Metsera’s top 20 shareholders.
Strategic Stakes: A Foothold in the Obesity Boom
The acquisition hands Pfizer entry into a market dominated by Eli Lilly and Novo Nordisk, where demand for GLP-1–based drugs like Mounjaro and Wegovy has outpaced supply.
Metsera’s lead candidates — MET-097i, a GLP-1 injectable, and MET-233i, which mimics the pancreatic hormone amylin — are still in early development but could generate $5 billion in combined peak annual sales, according to analysts at Leerink Partners.
However, analysts also warned that Pfizer is paying a steep price. Bernstein’s Courtney Breen estimated the deal assumes $11 billion in revenue by 2040, nearly double Metsera’s own forecasts. “The math only works if Pfizer can execute flawlessly,” she noted, pointing to rising skepticism about long-term GLP-1 pricing and margins.
Novo’s Exit, Pfizer’s Gamble
For Novo Nordisk, the collapse of its bid underscores its increasing regulatory challenges in the U.S. and growing pressure to maintain leadership in obesity treatments as Lilly and now Pfizer expand aggressively.
For Pfizer, the acquisition is both a comeback and a gamble. After past failures in developing weight-loss drugs, the pharma giant is betting that Metsera’s innovative dual-hormone approach could reignite growth after declining COVID vaccine revenues.
“This deal shows Pfizer is done sitting on the sidelines,” said one New York biotech analyst. “They’re reloading for the next trillion-dollar health frontier — metabolic medicine.”
What Comes Next
Pfizer expects to close the deal soon after Metsera’s November 13 shareholder meeting. If successful, the merger will mark a new phase in the global obesity drug arms race — where biotech innovation, pricing power, and regulatory scrutiny are now colliding at scale.
For investors, one thing is clear: the battle for control of the world’s next blockbuster drug category has only just begun — and Pfizer now holds the upper hand.
